HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes. Jun 26 2023
E2951 D-Desthiobiotin D-Desthiobiotin(Dethiobiotin) is a biotin derivative used in affinity chromatography and protein chromatography. D-Desthiobiotin also can be used for protein cross-linking agent, protein and cell labeling, detection and isolation. Jun 26 2023
D4006 Anetumab-MMAE Anetumab-MMAE is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin (MSLN) antibody and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). Jun 26 2023
D4007 Clivatuzumab-MMAE Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) composed of a humanized anti-mucin (MUC1) monoclonal antibody and a anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). Jun 26 2023
D4009 Indusatumab vedotin Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate (ADC) composed of an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody and a anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE). Jun 26 2023
D4010 Lifastuzumab vedotin Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer. Jun 26 2023
D4011 Anetumab ravtansine Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors. Jun 26 2023
D4012 Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Jun 26 2023
D4013 Zilovertamab vedotin Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies. Jun 26 2023
D4015 Farletuzumab-MMAE Farletuzumab-MMAE is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity. Jun 26 2023
D4016 Iladatuzumab vedotin Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. Jun 26 2023
D4017 Pinatuzumab vedotin Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Jun 26 2023
D4019 Sirtratumab vedotin Sirtratumab Vedotin (ASG-15ME), is an antibody-drug conjugate (ADC) composed of SLTRK6 (SLIT and NTRK like family member 6, "SLIT and NTRK-like family, member 6") and cytotoxic agent monomethyl auristatin E (MMAE). It delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6. SIRTRATUMAB VEDOTIN has the potential for Bladder Cancer, Metastatic urothelial cancer research. Jun 26 2023
D4021 Codrituzumab-MMAE Codrituzumab-MMAE, is an antibody-drug conjugate composed of a anti-GPC3 monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker. Jun 26 2023
D4022 Cetuximab-MMAE Cetuximab-MMAE is an antibody-drug conjugate composed of a anti-EGFR monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker. Jun 26 2023
E2944 Norepinephrine hydrochloride Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors. Jun 24 2023
E1327 CWI1-2 hydrochloride CWI1-2 hydrochloride is an inhibitor of IGF2BP2 that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects. Jun 24 2023
E1249 Blebbistatin Blebbistatin is a selective inhibitor of non-muscle myosin II (NMII). It also potently inhibits several striated muscle myosins as well as vertebrate nonmuscle myosin IIA and IIB with IC50 values ranging from 0.5 to 5 μM. It promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Jun 24 2023
E2966 Lysophosphatidylcholines Lysophosphatidylcholines are a class of chemical compounds which are derived from phosphatidylcholines. Lysophosphatidylcholine is produced from phospholipids by the action of phospholipase A2 (PLA2). It also has pro-inflammatory properties through its activation and modulation of various signaling pathways, including the ERK pathway as well as through protein tyrosine kinase and G protein-coupled receptor (GPCR) signal transduction. It plays a critical role in allergic airway disease manifestation. Jun 24 2023
E2963 Carmine Carmine (Carmine red), a natural red dye extracted from the dried females of the insect Dactylopius coccus var. Costa (cochineal). Carmine is a widely used food additive. Carmine provokes both an immediate hypersensitivity and a delayed systemic response with cutaneous expression. Jun 24 2023